Howard G. Welgus - 31 May 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Director
Signature: /s/ Scott Burrows as, Attorney-in-Fact for Howard Welgus
Issuer symbol: ARQT
Transactions as of: 31 May 2023
Transactions value $: $0
Form type: 4
Date filed: 02 Jun 2023, 18:54
Previous filing: 18 Apr 2023
Next filing: 06 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Award	$0	+4.38K	+2.64%	$0.00	170K	31 May 2023	Direct	F1
holding	ARQT	Common Stock						25K	31 May 2023	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Award	$0	+12.2K		$0.00	12.2K	31 May 2023	Common Stock	12.2K	$7.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
F2	The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3	The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023.